

	Folding line	
Black		Keyline

give you medicine to treat your skin condition. She or he may pause or stop treatment if your skin reaction worsens. If you have any further questions about your treatment, please contact your doctor. IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS • This patient is being treated with Padcev (enfortumab vedotin), which can cause severe skin reactions, including SJS and TEN	(predominantly during the first cycle of treatment). • Symptoms include rash or itching that continues to get worse or comes back after treatment, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat or genital area, fever or flu-like symptoms or swollen lymph nodes. • Fever or flu-like symptoms may be the first sign of a skin reaction. Patients should be monitored starting with the first cycle and throughout treatment for skin reactions.	Topical corticosteroids/ antihistamines can be considered for mild to moderate skin reactions. • If SJS or TEN is suspected or if bullous lesions occur, immediately withhold treatment and refer for specialised care; histologic confirmation is critical to early recognition, as diagnosis and intervention can improve prognosis. • If SJS or TEN, Grade 4 or recurrent Grade 3 skin reactions occur, permanently discontinue treatment.	• Withhold treatment for Grade 2 with fever, worsening Grade 2 or Grade 3 skin reactions until Grade ≤1 and resume at the same dose level or consider dose reduction by one dose level; consider referral to specialised care. Please contact the patient's Haematologist/Oncologist for more information and consult the Product Information for enfortumab vedotin available at https://www.ema.europa.eu/.	My name: My contact number: Emergency contact: Emergency contact number: Name of Haematologist/Oncologist/Oncology Nurse: Contact number:	After-hours contact number: Name of my Hospital: My Hospital contact number: PADCEV start date:	This patient card was last revised in 04/2022.
---	---	---	--	---	---	---